cystic fibrosis

Motif Bio has received an award from the Cystic Fibrosis Foundation, which will fund important in vitro testing to advance the development of iclaprim for the treatment of lung infections in patients with cystic fibrosis more

16 Jan 2018 11:00 News

Motif Bio’s investigational drug candidate, iclaprim, has been granted orphan drug designation by the US Food and Drug Administration (FDA) for the treatment of Staphylococcus aureus lung infections in patients with cystic fibrosis. more

18 Sep 2017 12:30 News

Concert Pharmaceuticals has initiated a phase one multiple ascending dose clinical trial with CTP-656 for cystic fibrosis more

12 Nov 2015 16:14 News

US group Savara Pharmaceuticals has secured $10 million in financial backing to develop AeroVanc, the trade name of the first inhaled antibiotic designed to address the growing number of MRSA lung infections in cystic fibrosis patients. more

16 Oct 2014 14:59

The Phase III confirmatory trial is referred to as ACT CF (ataluren confirmatory trial in cystic fibrosis) and the primary endpoint is lung function as measured by relative change in percent predicted forced expiratory volume in one second, or FEV1. more

2 Jul 2014 12:03 News